CHS
Charlotte, North Carolina, 28203, United States
Completed
NCT Number: NCT02883400
Spironolactone After Liver Transplant
To study spironolactone to prevent calcineurin inhibitor (CNI) kidney injury.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
About this study
The aim of this study is to determine if spironolactone decreases nephrotoxicity from calcineurin inhibitors in liver transplant recipients and to determine the best study of renal function in liver transplant recipients.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- liver transplant
Exclusion criteria
- dual organ transplant
Treatment and study plan
Spironolactone
Drugspironolactone 25 mg up to 50 mg
Primary outcomes
-
Glomerular Filtration Rate (GFR)
Time frame: 18 months
The primary analyses were based on the difference between each estimated GFR measure and iothalamate scan.
Sponsors and collaborators
Lead sponsor
Wake Forest University Health Sciences
Other
Registry information
Official study title
Spironolactone to Prevent or Delay Calcineurin Inhibitor (CNI) Toxicity in Liver Transplant Recipients
Important dates
- Study start
- 2014
- Primary completion
- 2018
- Study completion
- 2018
- First posted
- Aug 30, 2016
- Registry last updated
- Apr 21, 2022
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.